SPY383.63+6.93 1.84%
DIA315.24+5.66 1.83%
IXIC12,920.15+196.68 1.55%

BRIEF-I-Mab Announces Multiple Clinical Advancements Of Its Differentiated CD73 Antibody Uliledlimab In China And The U.S.

· 02/05/2021 08:10
BRIEF-I-Mab Announces Multiple Clinical Advancements Of Its Differentiated CD73 Antibody Uliledlimab In China And The U.S.

- I-Mab IMAB.O:

  • I-MAB ANNOUNCES MULTIPLE CLINICAL ADVANCEMENTS OF ITS DIFFERENTIATED CD73 ANTIBODY ULILEDLIMAB IN CHINA AND THE U.S.

  • I-MAB - TOPLINE RESULTS FROM U.S. PHASE 1 STUDY DEMONSTRATE SAFETY AND CLINICAL ACTIVITY

  • I-MAB - IN CHINA, I-MAB IS ADVANCING PHASE 1/2 DOSE ESCALATION AND COHORT EXPANSION STUDY OF ULILEDLIMAB

Source text for Eikon: ID:nPn1mk5Fpa

Further company coverage: IMAB.O


((Reuters.Briefs@thomsonreuters.com;))